WA-UNAVETS
20.9.2021 14:05:05 CEST | Business Wire | Press release
UNAVETS (“UNAVETS”), a European platform for veterinary centers with over 43 practices across Spain and Portugal, announced today their partnership with Petabyte Technology (“Petabyte”), a leading veterinary software company, to join the newly established Petabyte Consortium, which is focused on cleaning and standardizing data to improve veterinary practices across the world.
Petabyte revolutionizes patient management for veterinary hospitals through its suite of software solutions, including Rhapsody, a cloud-based Practice Information Management System (PIMS); Petabyte Analytics, an enterprise-level analytics platform; and Boop, a mobile application simplifying the pet care experience for pet parents. With innovative features such as standardized data, comprehensive wellness plans, virtual check-in, on-the-go communications, and a built-in payment system, Petabyte enables doctors to deliver exceptional care to pets and their families.
“Petabyte was founded with a mission to simplify veterinary operations to help doctors and staff care for pets and their families,” said Michael Hyman, Co-Founder and Chief Executive Officer of Petabyte. “UNAVETS’ mission of supporting vets so they can focus on delivering the best healthcare is a goal we share, making this collaboration a natural choice. Furthermore, partnering with UNAVETS is another step towards setting the industry standard on a global level through next-generation software.”
UNAVETS’ corporate group will start by leveraging Petabyte’s analytics platform as they continue to expand across EMEA, switching to localized versions of Petabyte’s products as they roll out. As the Petabyte Consortium continues to expand, Petabyte and UNAVETS invite other forward-thinking veterinary partners and groups to collaborate on using Petabyte’s software to transform the future of pet care on a global stage through Petabyte’s suite of software solutions. UNAVETS is the third group to join Petabyte’s Consortium with more updates expected to be released as the Consortium continues to welcome new partners.
“UNAVETS’ key focus is elevating the level of healthcare for all pets and their families. This partnership was formed because we strongly believe that Petabyte’s next generation software will expand our ability to support that mission on multiple fronts,” comments Junko Sheehan, Founder and Chief Executive Officer of UNAVETS. “The ‘customer journey’ of today’s pet parents requires a digitally forward-thinking approach with mobile check-in, check-out, digital records, seamless online booking, etc., and we believe that Petabyte’s next generation of software is capable of providing this and much more. As the pandemic has increased the demand for veterinary healthcare worldwide, we hope that providing best-in-class software solutions to clinics will be important to alleviate excess demands on our vets, so they can focus on what they love doing – providing the best care for our pets.”
Founded in 2019, Petabyte’s mission is to give veterinary healthcare practitioners greater understanding and control over their business using cloud-based technology. Petabyte is a unique enterprise practice management solution that allows veterinary practices to run more efficient operations and deliver better patient veterinary care. Petabyte considers a practice’s needs by offering a product that emphasizes a simple design and intuitive usability. It also offers robust customer support through teams equipped to assist veterinary practices, both large and small. The company brings together unique talent with decades of experience in the veterinary industry and in building cutting-edge technology to deliver the best practice management solution on the market. For more information, please visit petabyte.technology .
UNAVETS has grown to over 43 practices and a team of over 385 employees across Spain and Portugal since January 2020. UNAVETS’ continued mission is to elevate the standard of healthcare for pets via continued professional development and operations. We offer practices that join our group real support and collaboration in HR/professional development, operations, IT, marketing/digital, finance and accounting, and facilities/equipment management via our corporate team of over 30 individuals. In December 2019, UNAVETS was financed with funds managed by Oaktree Capital Management, L.P. (“Oaktree”). Oaktree is a leader among global investors specializing in alternative investments, managing $140 billion in assets as of September 30, 2020. Oaktree’s core European strategy manages more than €4.5 billion in assets under management. For more information, please visit unavets.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210920005059/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
